Immunoblue, LLC
Publicly observedBaltimore, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Baltimore | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Immunoblue, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | ZGGMBZWMF5H3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant3 Sept 2024Publicly observed
NIH SBIR/STTR award: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles
USD 1,106,515.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant3 Sept 2024Publicly observed
NIH SBIR/STTR award: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles
USD 1,135,290.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.